This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Drug management of atrial fibrillation

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

There are three main therapeutic aims in the drug treatment of atrial fibrillation:

  • control of the ventricular rate (1):
    • in patients with permanent AF, who need treatment for rate-control:
      • beta-blockers or rate-limiting calcium antagonists should be the preferred initial monotherapy in all patients
      • digoxin should only be considered as monotherapy in predominantly sedentary patients
  • chemical cardioversion to sinus rhythm:
    • class IV, I and III drugs
  • prevention of thromboembolism:
    • anticoagulation with warfarin or aspirin

Note: there is evidence from two large randomised trials (2,3) that have shown that a rate-control strategy is at least as effective as rhythm control

  • there was a strong trend for patients in the rate-control group to have fewer major clinical events (and patients in this treatment group had fewer adverse events)
  • t is unclear when a rhythm-control strategy might be preferred. Possible instances might be (4):
    • a recent-onset AF with a low risk of recurrence - in a case where there is an obvious precipitant and no underlying structural heart disease, for example, a patient with a pyrexial illness such as pneumonia or AF occurring after an alcoholic binge or following an operation
    • intolerable symptoms despite adequate rate control
    • patients at high risk from warfarin or aspirin therapy

  • NICE have stated that (1):
    • When to offer rate or rhythm control Rate control
      • offer rate control as the first-line strategy to people with atrial fibrillation, except in people:
        • whose atrial fibrillation has a reversible cause
        • who have heart failure thought to be primarily caused by atrial fibrillation
        • with new-onset atrial fibrillation
        • with atrial flutter whose condition is considered suitable for an ablation strategy
        • to restore sinus rhythm for whom a rhythm control strategy
        • would be more suitable based on clinical judgement
      • offer either a standard beta-blocker (that is, a beta-blocker other than sotalol) or a rate-limiting calcium-channel blocker as initial monotherapy to people with atrial fibrillation who need drug treatment as part of a rate control strategy. Base the choice of drug on the person's symptoms, heart rate, comorbidities and preferences when considering drug treatment

      • digoxin should only be considered as monotherapy if
        • the person does no or very little physical exercise or
        • other rate-limiting drug options are ruled out because of comorbidities or the person's preferences

      • if monotherapy does not control symptoms, and if continuing symptoms are thought to be due to poor ventricular rate control, consider combination therapy with any 2 of the following:
        • a beta-blocker
        • diltiazem
        • digoxin

      • do not offer amiodarone for long-term rate control

Notes:

  • previous NICE guidance had stated (5):

    • in patients with permanent AF, where monotherapy is inadequate:
      • to control the heart rate only during normal activities, beta-blockers or rate-limiting calcium antagonists should be given with digoxin
      • to control the heart rate during both normal activities and exercise, rate-limiting calcium antagonists should be given with digoxin
    • patients unsuitable for cardioversion include those with:
      • contraindications to anticoagulation
      • structural heart disease (e.g. large left atrium >5.5 cm, mitral stenosis) that precludes long-term maintenance of sinus rhythm
      • a long duration of AF (usually >12 months)
      • a history of multiple failed attempts at cardioversion and/or relapses, even with concomitant use of antiarrhythmic drugs or non-pharmacological approaches
      • an ongoing but reversible cause of atrial fibrillation (e.g. thyrotoxicosis)

Reference:

  1. NICE (April 2021). Atrial Fibrillation.
  2. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
  3. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
  4. Prescriber 2003; 14(14): 25-33.
  5. NICE (June 2006). Atrial Fibrillation.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.